"By using lithium metal cathode material, the energy density is three times higher than that of batteries currently on the market, and the charging speed is twice as fast."
This is actually a technology that Earth originally had, but due to various difficulties, this technological route has remained only in the laboratory.
For example, lithium metal expands during charging and discharging, damaging the battery structure. Lithium metal is also inferior to mainstream solid electrolyte materials, and there is a high possibility of explosion.
This lithium battery technology is not a mature technology of the Mage Alliance, but rather an improvement by Zheng Li based on immature technology from Blue Star.
The Mage Alliance's energy system is not lithium batteries at all; they mainly rely on bioenergy and use a small amount of solid high-energy fuels.
The Mage Alliance has a systematic theoretical framework for constructing chemical materials, and their advancements in computational chemistry are far ahead of the rest of the world.
Zheng Li used BioCloud to calculate the structure of lithium metal and analyzed the lithium metal cathode structure that best meets the requirements for large-scale commercialization.
At the same time, a novel graphene structure coating is introduced as an intermediate to prevent the lithium electrode from reacting directly with the solid electrolyte.
All the executives present were shocked because they had never heard of Zheng Li knowing anything about lithium batteries.
"Chairman Zheng, can this technology be implemented on a large scale? Or is it just a laboratory product?" Cheng Gang's question went straight to the heart of the matter.
Laboratory products are a long way from commercial application.
The most important aspect of commercially viable products is cost.
The costs here include not only manufacturing costs, but also labor costs.
For example, the manufacturing cost of endorphins, the first product of Kechuang Biotechnology, is not high, but the labor cost is very high.
Skilled workers in the large-scale industrial production of endorphins require at least six months of training to achieve a 95% yield rate.
Upon hearing this, Cheng Gang's first reaction was that the novel lithium metal electrode structure must require arranging each atom individually to create a unique structure.
This approach makes large-scale commercial use impossible.
The cost is too high.
Zheng Li: "The cost of manufacturing in the laboratory is about twice that of ordinary lithium battery cathode materials. If large-scale industrial production is carried out, the cost can be reduced further."
"Furthermore, I also intend to license the lithium metal cathode through patents; we will not produce it directly."
In recent years, the new energy industry chain has been booming, and the stock prices of companies in the upstream and downstream of the new energy industry chain have at least doubled.
While the market wasn't as hot as it was in 2021, the stock prices of high-quality new energy companies continued to rise.
However, some companies that have newly built production capacity but cannot find buyers saw their stock prices fluctuate at high levels before falling all the way down.
Because the industry expanded its capacity too much in 2020 and 2021, not all of that capacity could be absorbed. Those who expanded their capacity first reaped the rewards, while those who expanded their capacity later suffered the consequences.
Once Kechuang Biotechnology announces its lithium battery technology, all companies producing cathode materials will be in trouble.
One or two limit-down days are definitely not enough to stop it.
Cheng Gang was overjoyed, as this was the biggest boon for the company. The ability to triple the capacity of lithium batteries meant that electric vehicles could truly compete with gasoline vehicles.
By 2025, Huaguo has set a target of 20% market penetration. Cheng Gang is confident that Kechuang Bio's lithium battery technology can double that penetration rate.
Penetration rate refers to the market share of electric vehicles, and a target of 20% is actually not high at all.
The bill signed by America stipulates that the penetration rate of electric vehicles in the United States should reach 50% by 2030.
Cheng Gang breathed a sigh of relief; he had finally found a way to make up for the huge losses he had suffered from investing in Abogen Biosciences and Stemirna Therapeutics.
Although listed company executives are prohibited from engaging in related-party transactions, they must issue an announcement in advance if they wish to purchase shares of their own company.
Relatives of listed company executives are also prohibited from making illegal purchases. For example, if a relative buys shares in a science and technology innovation company and then positive news breaks shortly afterward, this will definitely be investigated by the China Securities Regulatory Commission (CSRC).
However, this is only in theory; there are many ways to implement it. For example, you could sign an agreement with a private equity firm to purchase the shares on your behalf, and then share the profits according to a certain percentage.
There are many ways to do it.
Moreover, it is not necessarily necessary to buy shares of Kechuang Bio.
With such a significant technological breakthrough in lithium batteries, companies involved in related new energy vehicle manufacturing are bound to see a surge in their stock prices.
All you need to do is leverage your investment to buy shares in new energy vehicle manufacturers.
Cheng Gang was mentally calculating how to proceed.
Zheng Li continued in the video conference: "Lithium battery technology patents are only licensed to Chinese automakers."
"Foreign car companies and joint venture car companies are not under consideration at all. You need to figure out the specific operation method and the public statement."
"Including our brain-computer interface VR, which can utilize entirely new battery technology."
“Licensing lithium cathode technology to mobile phone manufacturers is not subject to this restriction.”
The executives present were puzzled, but no one asked a question in public.
Because of such sensitive issues, the senior executives of Kechuang Biotechnology entrusted Li Miaomiao to ask Zheng Li, and then Li Miaomiao would judge whether or not to reveal the reasons for Zheng Li's actions to the senior officials.
As for why this tradition was formed, it may be because once when an executive asked a question, Zheng Li acted as if he hadn't heard it and moved on to the next agenda item.
It's quite embarrassing to be ignored by the top boss during an executive meeting.
"I will hire a lawyer to register the patent as soon as possible so that the news can be spread. I will send the samples back and give them to domestic car manufacturers for testing."
"Only I know the specific structure and manufacturing method of lithium metal cathode, so there is no leak."
After the meeting, all the executives were invigorated. Influenced by this positive news, it would be no problem for the stock price of Kechuang Bio to double.
Super battery technology will be used in all new energy vehicles in China in the future. The unit price of the car will be much higher than that of a mobile phone, and the patent licensing fees that can be collected will also be much higher than those of a mobile phone.
The executives chatted privately after the board meeting and discussed the following:
"The patent licensing fee for brain-computer interface with mobile phone is two hundred, so charging two thousand for the patent licensing fee for super battery is not unreasonable."
"Two thousand? That's too narrow-minded. Do you know how much CATL demanded in its patent lawsuit?"
"How many?"
"Twenty-four percent of the product's total profit, multiplied by ten percent."
"That's equivalent to 2.4 percent of the total profit, which isn't very high."
"The problem is that this manufacturer's product only infringed on a very small part of CATL's patents, and it didn't use CATL's patents from beginning to end. They have to pay nearly 100 million yuan in compensation."
"No one can steal our patents even if they want to."
"Who said that endorphins were stolen by Indians? I've always said that patents shouldn't be licensed to foreign pharmaceutical companies. Data from the first half of this year shows that more than 20 percent of endorphins worldwide come from India."
"The problem is that Indians don't pay patent licensing fees, and the Indian courts simply won't accept your lawsuit."
Continue read on readnovelmtl.com
